Obicetrapib hemicalcium

Overview

Obicetrapib hemicalcium (TA-8995 hemicalcium) is an orally active cholesteryl ester transfer protein ( CETP ) inhibitor. Obicetrapib hemicalcium shifts the plasma lipoprotein profile toward more HDL-C particles, reduces circulating PCSK9 levels, increases hepatic LDLR expression and LDLR mRNA levels, and promotes hepatic clearance of VLDL remnants. Obicetrapib hemicalcium increases the number of large HDL particles, reduces the number and area of atherosclerotic lesions and alleviates lesion severity, increases the proportion of unaffected arterial segments, improves lesion stability, and promotes regression of aortic root lesions. Obicetrapib hemicalcium also exerts a synergistic effect with Ezetimibe ( HY-17376 ) to reduce non-HDL-C levels and improve atherosclerosis. Obicetrapib hemicalcium can be used in studies related to atherosclerosis and dyslipidemia.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Chronic Disease and Inflammation | Products > Disease Areas > Atherosclerosis and Inflammation | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > CETP | Products > Signaling Pathways > PCSK9 | Products > Signaling Pathways > LDLR

Product Information

• Catalog No.: HY-18778C
• CAS No.: 866399-89-5
• Molecular Formula: C32H31F9N4O5·1/2Ca
• Molecular Weight: 742.65
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source